It will also upregulate the purinergic receptor P2Ry2 in AML cells and thereby activate PI3K-AKT signaling; inhibition of this pathway has therefore potentiated the antileukemic effects of selinexor in experimental models [199]. Here, AKT1 is linked to acute myeloid leukemia.